Jardiance Insurance Denied? How to Appeal Your Empagliflozin Denial

Jardiance (empagliflozin) is more than a diabetes medication. It is FDA-approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established heart disease, and to reduce hospitalizations for heart failure and slow chronic kidney disease progression. Despite its proven clinical benefits, insurance companies frequently deny Jardiance — often citing cost or step therapy requirements. If you've been denied, here's how to fight back.

What Jardiance Treats and Why Patients Need It

Jardiance belongs to a class of drugs called SGLT2 inhibitors. Originally approved for type 2 diabetes, Jardiance has received expanded FDA indications for:

• Reducing cardiovascular mortality in adults with type 2 diabetes and established cardiovascular disease
• Reducing hospitalization for heart failure in adults with reduced ejection fraction
• Slowing progression of chronic kidney disease (CKD)

These expanded indications make Jardiance uniquely important for patients who have both metabolic disease and serious organ damage. For many patients with diabetic kidney disease or heart failure, Jardiance is considered a cornerstone of treatment by their cardiologist or nephrologist — not just an optional diabetes add-on.

Common Denial Reasons for Jardiance

Step therapy requirements: Insurers commonly require patients to first try metformin — and often another second-line agent like a sulfonylurea — before they'll approve an SGLT2 inhibitor.

Formulary exclusion or non-preferred tier placement: Some plans exclude Jardiance from the formulary entirely, or place it on a high-cost specialty tier, making it unaffordable without an exception.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not approved: Jardiance requires prior authorization at most major plans. Denials often occur due to missing documentation of prior therapies or comorbidities.

"Not medically necessary" for non-diabetes indication: If Jardiance is prescribed primarily for heart failure or CKD without a diabetes diagnosis, some plans may question whether coverage applies under their diabetes-specific coverage provisions.

Cheaper alternatives available: Insurers may point to Farxiga (dapagliflozin) — another SGLT2 inhibitor — as a preferred formulary alternative.

Step-by-Step: How to Appeal a Jardiance Denial

Step 1: Read the denial letter carefully. Identify whether the denial is due to step therapy, prior auth, formulary exclusion, or lack of medical necessity. Each reason requires a different appeal approach.

Step 2: Have your prescriber document the full clinical picture. A Letter of Medical Necessity should explain your diabetes control, cardiovascular status, renal function (GFR, urine albumin-to-creatinine ratio), prior medications, and the specific FDA indication supporting Jardiance use.

Step 3: Document failed or inadequate prior treatments. Show that you have tried required step therapy agents, or explain why they are contraindicated or medically inappropriate for you.

Step 4: Submit the internal appeal with complete documentation. Include the LMN, labs, office notes, and any relevant specialist letters (cardiologist, nephrologist).

Step 5: Request peer-to-peer review. This is especially effective when your specialist (cardiologist or nephrologist) makes the call — they can speak to the medical director with clinical authority.

Step 6: File an external appeal if needed. External Independent Review: Complete Guide" class="auto-link">External review organizations frequently side with patients when FDA-approved medications are denied without sound clinical justification.

What to Include in Your Jardiance Appeal Letter

• Patient identifying information and claim/policy numbers
• The specific indication for which Jardiance is prescribed (diabetes, heart failure, CKD)
• Relevant labs: HbA1c, eGFR, urine ACR, BNP/NT-proBNP, ejection fraction if applicable
• History of prior medications tried with dates and outcomes
• Letter of Medical Necessity from cardiologist or nephrologist if applicable
• References to FDA-approved indications for empagliflozin
• Citation of ACC/AHA heart failure guidelines recommending SGLT2 inhibitors
• KDIGO CKD guidelines citation if kidney disease is the primary indication
• Request for peer-to-peer review

Success Tips for Jardiance Appeals

Lead with the cardiovascular indication. If you have established cardiovascular disease and type 2 diabetes, your appeal should center on Jardiance's FDA-approved cardiovascular mortality reduction indication — not just glucose control. This is harder for insurers to deny than a simple diabetes add-on argument.

Bring in your specialist. A nephrologist's or cardiologist's letter carries more weight than a primary care LMN alone when the indication extends beyond glucose control.

Distinguish from Farxiga if needed. If your plan prefers Farxiga, ask your doctor if there's a clinical reason specific to empagliflozin (e.g., prior experience, specific trial data, patient tolerance). Documenting this distinction strengthens an exception request.

Know the EMPEROR and EMPA-REG trials. These landmark trials are the clinical foundation for Jardiance's cardiovascular and renal indications. Referencing them demonstrates this isn't an experimental request — it's guideline-recommended care.

Don't give up after one denial. Each level of appeal is a fresh opportunity. Many Jardiance denials are reversed on first internal appeal when proper documentation is provided.

Fight Back With ClaimBack

You deserve access to the medication your doctor prescribed. ClaimBack helps patients navigate complex insurance denials with clear, step-by-step guidance and AI-assisted appeal letter drafting.

Start your Jardiance appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals